Lavender Essential Oil as Treatment for Chronic Migraine: A Protocol for Non-Inferiority Randomized Controlled Trial
Abstract
This study is a randomized, investigator-blinded, controlled phase III clinical trial designed to compare the efficacy of daily atomized inhalation of lavender essential oil versus 50 mg sumatriptan tablets among Australians aged 18–65 years with chronic migraine, with a 3-month follow-up period. The primary outcome is the monthly reduction in headache days, defined as an improvement from moderate or severe pain to mild or no pain. Eligible participants diagnosed with chronic migraine by general practitioners and providing informed consent are randomized 1:1 to the intervention group (lavender essential oil) or the control group (sumatriptan tablets). This protocol aims to evaluate whether lavender essential oil is non-inferior to standard pharmaceutical treatment for chronic migraine management.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.